Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q1 2025 Earnings Presentation
18 slides from Prestige Consumer Healthcare's earnings presentation, Aug 8, 2024
Slide 1: First Quarter FY 2025 Results
First Quarter FY 2025 Results August 8th, 2024
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 25 Outlook FIRST QUARTER FY 25 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update FIRST QUARTER FY 25 RESULTS
Slide 5: FY 25 Off to a Good Start in Q1
FY 25 Off to a Good Start in Q1 ◼ Quarterly Revenue of $267.1 million, ahead of expectations Q1 FY 25 Sales ◼ Outperformance highlighted by Eye & Ear Care sales timing and continued Drivers International growth ◼ Continue to execute proven brand-building strategy ◼ Gross Margin slightly down due to
Slide 6: Summer's Eve Progressing Towards Return to Growth
Summer’s Eve Progressing Towards Return to Growth Core Portfolio Stabilizing Innovation Supported by Engaging Campaigns Sprays, Mists & Other Washes & Cleansing Cloths ◼ Summer’s Eve Odor Protection product off to a strong early start ◼ Washes & Cloths performing well; Sprays remain challenged ◼ Sup
Slide 7: Hydralyte: Proven Long-Term Brand-Building Example
Hydralyte: Proven Long-Term Brand-Building Example TTM Sales* Growth Multiple Touchpoints Across Retail & Digital Retail Digital +16% CAGR Omnichannel Campaign Reaching Over 3MM Unique Consumers Across Each Channel Respectively Q1 FY20 Q1 FY25 Household penetration of approximately 10%; continuing t
Slide 8: II. Financial Overview
II. Financial Overview FIRST QUARTER FY 25 RESULTS
Slide 9: Q1 FY 25 Performance Highlights
Q1 FY 25 Performance Highlights (4.4%) Revenue(1) of $267.1 million, down 4.3% vs. prior year excluding foreign currency(1) $279.3 $267.1 (15.2%) $94.0 EBITDA(2) of $79.7 million down vs. prior year $79.7 owing to timing of costs (15.1%) $1.06 $0.90 Revenue EBITDA (2) Adj. Diluted EPS (2) Adjusted D
Slide 10: FY 25 First Quarter Consolidated Financial Summary
FY 25 First Quarter Consolidated Financial Summary 3 Months Ended Comments Q1 FY 25 Q1 FY 24 % Chg ◼ Organic Revenue(1) down 4.3% vs. prior year Total Revenue $ 267.1 $ 279.3 (4.4%) – Clear Eyes sales above expectations via shipment Gross Profit 146.0 154.7 (5.6%) timing % Gross Margin 54.7% 55.4% –
Slide 11: Industry Leading Free Cash Flow Trends
Industry Leading Free Cash Flow Trends Free Cash Flow Comments Q1 FY 25 Q1 FY 24 ◼ Q1 Free Cash Flow(2) of $53.6 million up vs. prior year 15.0% – Maintaining full-year free cash flow outlook(5) – Strong business attributes continue to drive Free Cash Flow ◼ Net Debt at June 30 of $1.1 billion(2); l
Slide 12: III. FY 25 Outlook
III. FY 25 Outlook FIRST QUARTER FY 25 RESULTS
Slide 13: FY 25 Outlook Unchanged
FY 25 Outlook Unchanged ◼ Remain well-positioned in dynamic macro environment ◼ Continue to emphasize brand-building on leading brands Top Line Trends ◼ Revenues of $1,125 to $1,140 million — Organic growth of approximately 1% ex-FX — Still anticipate Clear Eyes supply disruptions to mostly abate by
Slide 14: Q&A
Q&A FIRST QUARTER FY 25 RESULTS
Slide 15: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated August 8, 2024 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Margi
Slide 16: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended June 30, 2024 2023 (In Thousands) GAAP Total Revenues $ 267,142 $ 279,309 Revenue Change (4.4%) Adjustments: Impact of foreign currency exchange rates - (169) Total adjustments $ - $ (169) Non-GAAP Organic Revenues $ 267,142 $ 279,14
Slide 17: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Diluted EPS Three Months Ended June 30, 2024 2023 Net Diluted Net Diluted Income EPS Income EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS $ 49,068 $ 0.98 $ 53,276 $ 1.06 Adjustments: Normalized tax rate adjustment(a) (4,030) (
Slide 18: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Adjusted Diluted EPS Low High Projected FY'25 GAAP Diluted EPS $ 4.48 $ 4.54 Adjustments: Normalized tax rate adjustment(a) (0.08) (0.08) Total Adjustments (0.08) (0.08) Projected FY'25 Non-GAAP Adjusted Diluted EPS $ 4.40 $ 4.46 (a) Income tax adjustme
Prestige Consumer Healthcare — Q1 2025 Earnings Presentation on 6ix